No Data
Duke Medical-B (06996.HK): The indication for the use of Xiwei'ao in the treatment of diffuse large B-cell lymphoma has been successfully included in the 2024 version of the national medical insurance pharmaceutical directory.
Gelonghui, November 28th | Deqi Pharmaceuticals-B (06996.HK) announced that Xevotio (Selinexor Tablets) has a new indication for the treatment of relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) adult patients who have received at least two lines of systemic therapy, and has been included in the 2024 National Reimbursement Drug List (NRDL) officially effective from January 1, 2025.
Announcement Highlights | Multiple pharmaceutical products from various pharmaceutical companies have been included in the national medical insurance catalog; bosideng's net income in the first half of the year increased by 23% year-on-year to approximate
① yuexiu property won a joint bid for a piece of land in shanghai for 7.9 billion yuan. What are the highlights? ② sanxun group saw a decline of over 60% in sales from January to October compared to the same period last year. How significant is the scale?
The new version of the medical insurance list adds 11 Chinese patent medicine varieties. Traditional Chinese medicine innovative drugs, classic famous prescriptions, and children's medications receive key support.
In 2024, the national medical insurance catalog was officially released today, with 91 pharmaceuticals newly added to the national medical insurance drug catalog, with an average price reduction of 63%; this time there are 11 new chinese patent medicines added, 10 of which are new drugs approved for marketing last year and this year.
How to adjust the new national medical insurance catalog? Here is the explanation.
1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.
New Indication of Antengene's Lymphoma Drug Included in China's National Reimbursement Drug List
Deqi Pharmaceuticals' Xiveiao has added new indications to the national medical insurance catalog, and the inclusion of medical insurance in the Asia-Pacific market continues to expand.
November 28, Grunenthal announced today that Deqi Pharmaceuticals-B (6996.HK) has added a new indication for Xevious (selecinib tablets) to the national medical insurance list, with medical insurance coverage for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who have previously received at least two lines of systemic treatment. The new version of the national medical insurance list will officially take effect on January 1, 2025. In July 2024, after being approved for the first time for the treatment of relapsed or refractory multiple myeloma (R/R MM), Xevious obtained a second indication in China for the treatment of R/
No Data
No Data